Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6451MR)

This product GTTS-WQ6451MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6451MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4480MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ3000MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ14403MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ2273MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ8174MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ4542MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ14567MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ11237MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI3902
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW